Open, Multicentre,Randomized Phase IV Trial to Evaluate Efficacy/Safety to Extend Treatment Duration With Peginterferon Alfa-2a+High Dose of Ribavirin Supporting Epo beta in Treatment of CHC in HIV-HCV Patients Who Not Clear Virus at Week 4

Trial Profile

Open, Multicentre,Randomized Phase IV Trial to Evaluate Efficacy/Safety to Extend Treatment Duration With Peginterferon Alfa-2a+High Dose of Ribavirin Supporting Epo beta in Treatment of CHC in HIV-HCV Patients Who Not Clear Virus at Week 4

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms PERICO
  • Most Recent Events

    • 08 Nov 2011 Results presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.
    • 02 Mar 2011 Interim results presented at the 18th Conference on Retroviruses and Opportunistic Infections.
    • 22 Jul 2009 Results of a ribavirin pharmacokinetic substudy presented at the 5th International AIDS Society (IAS) conference on HIV Pathogenesis, Treatment and Prevention.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top